A bipartisan group of lawmakers has asked the U.S. government to consider new rules restricting U.S. biotech companies from conducting clinical trials with entities linked to the Chinese military.
In a Jan. 9 letter to Commerce Secretary Gina Raimondo, the House Select Committee on the Chinese Communist Party said the proposed restrictions will “help ensure U.S. biotechnology does not fall into the hands of the PRC,” referring to the acronym of communist China’s official name, the People’s Republic of China.
The letter, signed by Reps. John Moolenaar (R-Mich.) and Raja Krishnamoorthi (D-Ill.), chair and ranking member of the committee, respectively, along with Rep. Neal Dunn (R-Fla.), said biotech competition between the United States and the PRC “will not only have implications for our national and economic security, but also for the future of healthcare and the security of American medical data.”
The letter cites Beijing’s 14th Five-Year Plan—which “identifies dominance in biotechnology as critical to ’strengthen the PRC’s science and technological power’ and calls to deepen military-civil science and technology collaboration in the sector”—and a publication by a former president of the Chinese military’s National Defense University, which discussed the potential to create new synthetic pathogens that are “more toxic, more contagious, and more resistant.”
The lawmakers praised the proposals issued by the Bureau of Industry and Security in July 2024 to expand export controls to military and intelligence end users as “a welcome update.” They suggested the measures could be further strengthened by requiring a license to conduct clinical trials with medical institutions linked to the People’s Liberation Army (PLA).
“Specifically, we recommend updating the definition of ‘Military End User’ to state medical infrastructure owned or operated by the national armed services of the PRC and other countries as appropriate constitutes a military end-use if a U.S. person is seeking to engage with the institution to conduct a clinical trial,” they added.
The Epoch Times reached out to the Commerce Department for comment and did not receive a response by publication time.
The letter is a sign of growing concern over China’s role in the biotechnology industry.
In August 2024, the same committee wrote to the Food and Drug Administration (FDA), asking the agency to ensure that U.S. clinical trials are not contributing to human rights abuses in China’s Xinjiang region or aiding the transfer of U.S. critical intellectual property to the PLA.
Citing official data, the letter said U.S. biopharmaceutical companies over the past decade had run hundreds of clinical trials that had at least one Chinese military entity among the research partners and conducted trials in hospitals in Xinjiang, “where the Chinese Communist Party (CCP) is engaged in genocide of the Uyghur population.”
Hellbound and Down 